利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.013 秒)

    DENIBULIN DI-HYDROCHLORIDE
    1.
    发明申请
    DENIBULIN DI-HYDROCHLORIDE 有权
    丹尼林二氢氯化物

    公开(公告)号：US20130041002A1

    公开(公告)日：2013-02-14

    申请号：US13560785

    申请日：2012-07-27

    申请人： Kale RUBY

    发明人： Kale RUBY

    IPC分类号： C07D235/32 ,  A61P35/00 ,  A61P9/10 ,  A61P19/02 ,  A61P17/06 ,  A61P27/02 ,  A61K31/4184 ,  A61P29/00

    CPC分类号： C07D235/32 ,  A61K31/4184 ,  A61K45/06

    摘要： MN-029 di-hydrochloride (MN-029.2HCl, Formula 2) is a potent vascular targeting agent. The present invention focuses on the synthesis and characterization of the di-hydrochloride salt MN-029 and the preparation of pharmaceutically acceptable formulations thereof. Methods are disclosed of using the compound and formulations thereof in the treatment of diseases that rely on the generation of neovasculature by angiogenesis for disease progression.

    摘要翻译： MN-029二盐酸盐（MN-029.2HCl，式2）是有效的血管靶向剂。 本发明着重于二盐酸盐MN-029的合成和表征及其药学上可接受的制剂的制备。 公开了使用该化合物及其制剂治疗依赖于通过血管发生用于疾病进展的新血管生成的疾病的方法。

    Amylin agonist pharmaceutical compositions containing insulin
    2.
    发明授权
    Amylin agonist pharmaceutical compositions containing insulin 失效
    胰岛淀粉样多肽激动剂含有胰岛素的药物组合物

    公开(公告)号：US6136784A

    公开(公告)日：2000-10-24

    申请号：US005240

    申请日：1998-01-09

    申请人： James L'Italien ,  Shankar Musunuri ,  Kale Ruby ,  Orville Kolterman

    发明人： James L'Italien ,  Shankar Musunuri ,  Kale Ruby ,  Orville Kolterman

    IPC分类号： A61K38/22 ,  A61K38/28 ,  A61K38/00

    CPC分类号： A61K38/22 ,  A61K38/28 ,  Y10S514/866

    摘要： The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier; and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.

    摘要翻译： 本发明涉及容器中的药物制剂，例如小瓶，预填充的药筒，预充式注射器或一次性笔，其包含在水系统中约0.01至约0.5％（w / v）的胰岛淀​​粉样多肽激动剂，优选普兰林肽 以及约0.02至约0.5％（w / v）的乙酸盐，磷酸盐，柠檬酸盐或谷氨酸盐缓冲液至最终组合物的pH为约3.0至约6.0，以及约1.0至10％（w / v） 的碳水化合物或多元醇增稠剂; 和任选的约0.005至1.0％（w / v）的选自间甲酚，苯甲醇，对羟基苯甲酸酯和苯酚的防腐剂。 这些制剂在冷冻或室温条件下保存时保持稳定性。 这样的制剂可以在相同的注射器中进一步与胰岛素组合以给予患者。

    Denibulin di-hydrochloride
    6.
    发明授权
    Denibulin di-hydrochloride 有权
    丹蛋白二盐酸盐

    公开(公告)号：US08633324B2

    公开(公告)日：2014-01-21

    申请号：US13560785

    申请日：2012-07-27

    申请人： Kale Ruby

    发明人： Kale Ruby

    IPC分类号： A61K31/4184 ,  C07D235/32

    CPC分类号： C07D235/32 ,  A61K31/4184 ,  A61K45/06

    摘要： MN-029 di-hydrochloride (MN-029.2HCl, Formula 2) is a potent vascular targeting agent. The present invention focuses on the synthesis and characterization of the di-hydrochloride salt MN-029 and the preparation of pharmaceutically acceptable formulations thereof. Methods are disclosed of using the compound and formulations thereof in the treatment of diseases that rely on the generation of neovasculature by angiogenesis for disease progression.

    摘要翻译： MN-029二盐酸盐（MN-029.2HCl，式2）是有效的血管靶向剂。 本发明着重于二盐酸盐MN-029的合成和表征及其药学上可接受的制剂的制备。 公开了使用该化合物及其制剂治疗依赖于通过血管发生用于疾病进展的新血管生成的疾病的方法。

    Formulations for amylin agonist peptides
    7.
    发明授权
    Formulations for amylin agonist peptides 失效

    公开(公告)号：US06410511B1

    公开(公告)日：2002-06-25

    申请号：US09005262

    申请日：1998-01-09

    申请人： James L'Italien ,  Shankar Musunuri ,  Kale Ruby

    发明人： James L'Italien ,  Shankar Musunuri ,  Kale Ruby

    IPC分类号： A61K3800

    摘要： The present invention is concerned with a pharmaceutical formulation in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen, comprising approximately 0.01 to about 0.5% (w/v) amylin agonist, preferably pramlintide, in an aqueous system along with approximately 0.02 to about 0.5% (w/v) of an acetate, phosphate, citrate, or glutamate buffer to a pH of the final composition of approximately 3.0 to about 6.0 as well as approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier; and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, parabens and phenol. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin in the same syringe for administration to a patient.